Liraglutide increases 24-h heart rate by reducing the cardiac parasympathetic activity of patients with type 2 diabetes: power spectral analysis of heart rate variability on 24-h Holter ECG recordings

Diabetology International

Volumn 6, Issue 1, 2015, Pages 26-32

  Hara, Kenji ^a   Aso, Yoshimasa ^a   Komatsu, Takaaki ^a   Nakamachi, Takafumi ^a   Sakai, Yoshihiko ^a   Takayanagi, Kan ^a   Kasai, Kikuo ^a   Inukai, Toshihiko ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Heart rate; Heart rate variation; Liraglutide; Power spectral analysis

Indexed keywords

LIRAGLUTIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; HEART RATE; HEART RATE VARIABILITY; HOLTER MONITORING; HUMAN; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PARASYMPATHETIC FUNCTION; POWER SPECTRAL ANALYSIS; PRIORITY JOURNAL; SPECTROSCOPY; STATISTICAL ANALYSIS;

EID: 84924967718     PISSN: 21901678     EISSN: 21901686     Source Type: Journal    
DOI: 10.1007/s13340-014-0170-2     Document Type: Article

References (23)

1. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87:1409–39.
2. Yamamoto H, Kishi T, Lee CE, Choi BJ, Fang H, et al. Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites. J Neurosci. 2003;23:2939–46.
3. Barragán JM, Eng J, Rodríguez R, Blázquez E. Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats. Am J Physiol. 1999;277:E784–91.
4. Yamamoto H, Lee CE, Marcus JN, Williams TD, Overton JM, et al. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest. 2002;110:43–52.
5. Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet. 2010;375:1447–56.
6. Mundil D, Cameron-Vendrig A, Husain M. GLP-1 receptor agonists: a clinical perspective on cardiovascular effects. Diab Vasc Dis Res. 2012;9:95–108.
7. Robinson LE, Holt TA, Rees K, Randeva HS, O’Hare JP. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open. 2013;3(1):1–16.
8. Agersø H, Jensen LB, Elbrønd B, Rolan P, Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia. 2002;45:195–202.
9. Spallone V, Ziegler D, Freeman R, Bernardi L, Frontoni S, Pop-Busui R, Stevens M, Kempler P, Hilsted J, Tesfaye S, Low P, Valensi P. On behalf of the Toronto Consensus Panel on Diabetic Neuropathy. Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes Metab Res Rev. 2011;27:639–53.
10. Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation. 2007;115:387–97.
11. Bernardi L, Spallone V, Stevens M, Hilsted J, Frontoni S, Pop-Busui R, Ziegler D, Kempler P, Freeman R, Low P, Tesfaye S, Valensi P. On behalf of the Toronto Consensus Panel on Diabetic Neuropathy. Investigation methods for cardiac autonomic function in human research studies. Diabetes Metab Res Rev. 2011;27:654–64.
12. Wakabayashi S, Aso Y. Adiponectin concentrations in sera from patients with type 2 diabetes are negatively associated with sympathovagal balance as evaluated by power spectral analysis of heart rate variation. Diabetes Care. 2004;27:2392–7.
13. Yasuda H, Sanada M, Kitada K, Terashima T, Kim H, Sakaue Y, Fujitani M, Kawai H, Maeda K, Kashiwagi A. Rationale and usefulness of newly devised abbreviated diagnostic criteria and staging for diabetic polyneuropathy. Diabetes Res Clin Pract. 2007;77(Suppl 1):S178–83.
14. Schönauer M, Thomas A, Morbach S, Niebauer J, Schönauer U, Thiele H. Cardiac autonomic diabetic neuropathy. Diab Vasc Dis Res. 2008;5:336–44.
15. Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012;8:728–42.
16. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L. LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374(9683):39–47.
17. Laude D, Baudrie V, Elghozi JL. Effects of atropine on the time and frequency domain estimates of blood pressure and heart rate variability in mice. Clin Exp Pharmacol Physiol. 2008;35:454–7.
18. Griffioen KJ, Wan R, Okun E, Wang X, Lovett-Barr MR, et al. GLP-1 receptor stimulation depresses heart rate variability and inhibits neurotransmission to cardiac vagal neurons. Cardiovasc Res. 2011;89:72–8.
19. Palatini P, Benetos A, Grassi G, Julius S, Kjeldsen SE, Mancia G, Narkiewicz K, Parati G, Pessina AC, Ruilope LM, Zanchetti A. European Society of Hypertension. Identification and management of the hypertensive patient with elevated heart rate: statement of a European Society of Hypertension Consensus Meeting. J Hypertens. 2006;24:603–10.
20. Okerson T, Chilton RJ. The cardiovascular effects of GLP-1 receptor agonists. Cardiovasc Ther. 2012;30:e146–55.
21. Wang B, Zhong J, Lin H, Zhao Z, Yan Z, He H, Ni Y, Liu D, Zhu Z. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials. Diabetes Obes Metab. 2013;15:737–49.
22. Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, Zdravkovic M, Düring M, Matthews DR. LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32:84–90.
23. Kim M, Platt MJ, Shibasaki T, Quaggin SE, Backx PH, Seino S, Simpson JA, Drucker DJ. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med. 2013;19:567–75.